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Neurotrophins are important for neuronal health and
function. Here, statins, inhibitors of HMG-CoA reduc-
tase and cholesterol lowering drugs, were found to
stimulate expression of neurotrophins in brain cells
independent of the mevalonate pathway. Time-
resolved fluorescence resonance energy transfer
(FRET) analyses, computer-derived simulation, site-
directed mutagenesis, thermal shift assay, and de
novo binding followed by electrospray ionization tan-
demmass spectrometry (ESI-MS) demonstrates that
statins serve as ligands of PPARa and that Leu331
and Tyr 334 residues of PPARa are important for
statin binding. Upon binding, statins upregulate neu-
rotrophins via PPARa-mediated transcriptional acti-
vation of cAMP-response element binding protein
(CREB). Accordingly, simvastatin increases CREB
and brain-derived neurotrophic factor (BDNF) in the
hippocampus of Ppara null mice receiving full-length
lentiviral PPARa, but not L331M/Y334D statin-bind-
ing domain-mutated lentiviral PPARa. This study
identifies statins as ligands of PPARa, describes
neurotrophic function of statins via the PPARa-CREB
pathway, and analyzes the importance of PPARa in
the therapeutic success of simvastatin in an animal
model of Alzheimer’s disease.
INTRODUCTION
Brain-derived neurotrophic factor (BDNF) and NT-3 are neuro-
trophins belonging to the NGF family of neuronal growth factors.
BDNF infusion in the substantia nigra of rodent brain protects
dopaminergic neurons, suggesting therapeutic prospects for
Parkinson’s disease. Moreover, the injection of BDNF in hippo-
campus and amygdaloid regions leads to the protection of
cholinergic neurons (Morse et al., 1993) and improvement in
cognitive impairment (Nagahara et al., 2009), implicating BDNFCelin Alzheimer’s disease. BDNF is also capable of repairing spiny
striatal interneurons in Huntington’s disease (Kells et al., 2004)
and remyelinating the lower motor neurons (Stadelmann et al.,
2002) in multiple sclerosis. Therefore, BDNF promotes both
structural and functional integrity of neurons to alleviate different
neurological disorders. Similarly, NT-3 protects damaged neu-
rons, stimulates neurogenesis and restores neuronal functions
in the CNS affected by neurodegenerative diseases (Abe,
2000; Cheng and Mattson, 1994). However, the mechanisms
by which the production of these neurotrophins could be thera-
peutically increased in the CNS are poorly understood.
Although statins are cholesterol-lowering drugs, lovastatin in-
hibits the activation of NF-kB and the expression of proinflam-
matory molecules in brain cells via modulation of the mevalonate
pathway, thus prompting investigation of the efficacy of statins
as an anti-inflammatory and neuroprotective drug (Pahan et al.,
1997). Therefore, in addition to cholesterol-lowering, statins are
currently known to control inflammation, attenuate cell prolifera-
tion and cell migration, favor vasodilation, modulate adaptive
immunity, and suppress oxidative stress via modulation of the
mevalonate pathway (Pahan, 2006; Roy and Pahan, 2011).
Here, we report that statins also exhibit a neurotrophic effect.
Different statins upregulate BDNF and NT-3 in neurons,
microglia, and astrocytes. Although most of the biological
functions of statins depend on their ability to inhibit the mevalo-
nate-cholesterol pathway, statins stimulate the expression of
neurotrophins independently of this pathway. Interestingly,
we have found that statins directly interact with two critical
residues Leu331 and Tyr334 located in the ligand-binding
domain of PPARa to regulate the transcription of CREB, leading
to expression of neurotrophic molecules. Finally, we demon-
strate that simvastatin increases BDNF and improves memory
and learning in an animal model of Alzheimer’s disease (AD) via
PPARa.
RESULTS
Different Statins Induce the Expression of BDNF and
NT-3 in Primary Glia and Neurons
Astrocytes are the predominant cell type in the CNS and we first
investigated the effect of time-dependent effect of simvastatinl Metabolism 22, 253–265, August 4, 2015 ª2015 Elsevier Inc. 253
on BDNF expression in astrocytes. Although simvastatin-medi-
ated increase in BDNFmRNA was not visible at 2 hr, marked up-
regulation was observed at 5 hr of stimulation (Figure S1A).
Accordingly, mevastatin, simvastatin, and pravastatin dose-
dependently upregulated the mRNA expression of BDNF and
NT-3 in mouse primary astrocytes (Figures S1B and S1C) and
microglia (Figures S1D and S1E). Consistently, our protein re-
sults show upregulation of BDNF and NT-3 in both astrocytes
andmicroglia by ELISA (Figures S1F and S1G) and immunocyto-
chemistry (Figures S1H and S1I). Similar to mouse astrocytes,
mevastatin dose-dependently increased the mRNA (Figures
S1J and S1K) and protein (Figure S1L) expression of BDNF in pri-
mary human astrocytes. Immunofluorescence analyses revealed
that both astrocytes (Figure S1M) and microglia (Figure S1N) in
the cortex of simvastatin-fed mice expressed higher levels of
BDNF than the brain of saline-fed mice. These results demon-
strate that statins are capable of stimulating BDNF and NT-3 in
glial cells in culture as well as in vivo in the brain. Earlier, Wu
et al. (2008) showed increase in BDNF in vivo in the brain by
simvastatin.
While astrocytes and microglia produce neurotrophic factors
under neurodegenerative conditions (Kerschensteiner et al.,
1999; Roy et al., 2007), neurons are major contributors of neuro-
trophic factors in normal brain (Maisonpierre et al., 1990). Similar
to glia, the different statins stimulated mRNA (Figures S1O and
S1P) and protein expression (Figures S1Q and S1R) of neurotro-
phins in mouse cortical neurons. To further confirm, we knocked
down the BDNF gene by small interfering (siRNA) (Figures S1S
and S1T) and found that siRNA knock down of BDNF decreased
the production of BDNF protein in simvastatin-treated cortical
neurons (Figure S1U). Furthermore, glutamate significantly
induced the production of BDNF in neurons (Figure S1U). Similar
to mouse cells, different statins also dose-dependently stimu-
lated the expression of neurotrophins in primary human neurons
(Figures S1V and S1W). Accordingly, oral administration of
simvastatin upregulated the neuronal expression of BDNF in
the cortex compared with vehicle-fed mice (Figure S1X). There-
fore, statins are also able to stimulate the expression of neurotro-
phic factors in neurons.
Statin-Induced Expression of BDNF and NT-3 Is
Independent of the Mevalonate Pathway
Next, we investigated the mechanism by which statins might up-
regulate the expression of neurotrophins in glia. Since statins
selectively inhibit HMG-CoA reductase, most of the known bio-
logical functions of statins depend on their ability to modulate
the mevalonate pathway (Endo et al., 1976; Pahan et al., 1997).
However, pretreatment with increasing doses of mevalonate
and farnesyl pyrophosphate (FPP) failed to abrogate the statin-
induced mRNA expression of neurotrophins in astrocytes (Fig-
ures 1A and 1B), suggesting that statins upregulate the expres-
sion of neurotrophic factors independently of mevalonate
metabolites. By contrast, mevalonate, FPP, and geranylgeranyl
pyrophosphate (GPP) dose-dependently abrogated simva-
statin-mediated inhibition of iNOS in IL-1b-stimulated astrocytes
(Figures 1C and 1D). Moreover, the selective inhibition of small
G proteins by dominant-negative mutants of p21ras (DRas) and
p21rac (DRac) failed to stimulate the mRNA expression of
BDNF (Figure 1E). On the other hand, both DRas and DRac254 Cell Metabolism 22, 253–265, August 4, 2015 ª2015 Elsevier Incinhibited the IL-1b-induced mRNA expression of iNOS in astro-
cytes (Figure 1F). Consistent with this finding, while the siRNA-
mediated knockdown of p21ras failed to increase the expression
of BDNF in astrocytes (Figure 1G), it downregulated iNOSprotein
(Figures 1H–1I) expression. Farnesyl pyrophosphate transferase
(FPT) transfers the farnesyl group to p21ras, resulting in mem-
brane attachment of p21ras and its activation. It was previously
reported that FPT inhibitor (FPTi) inhibited the downstream acti-
vation of various inflammatory pathways such as NF-kB (Pahan
et al., 1997). Interestingly, FPTi had no stimulatory effect on the
mRNA expression of BDNF in astrocytes (Figure 1J), suggesting
that the farnesylation-p21ras pathway is not involved in the
upregulation of neurotrophic factors. Similarly, geranylgeranyl
transferase transfers the geranylgeranyl group to p21rac for its
membrane attachment and activation. Similar to FPTi, geranyl-
geranyl transferase inhibitor (GGTi) also failed to induce the
mRNA expression of BDNF (Figure 1J), indicating that the
geranylgeranylation-p21rac pathway is also not involved in
the stimulation of neurotrophic factors. However, as expected,
both FPTi and GGTi suppressed the IL-1b-induced expres-
sion of iNOS in astrocytes (Figures 1K and 1L). Taken together,
these data suggest that statins employ two independent
signaling pathways for their neurotrophic and anti-inflammatory
effects.
The Role of PPARa in Statin-Induced Expression of
Neurotrophic Factors in Glia
Simvastatin inhibits IL-1b-induced mRNA (Figures 2A and 2B)
and protein (Figures 2C and 2D) expression of iNOS equiva-
lently in wild-type (WT) and Ppara null astrocytes, suggesting
that simvastatin does not require PPARa to suppress iNOS.
We next examined whether PPARa was involved in statin-
mediated expression of neurotrophic factors in glia. Interest-
ingly, simvastatin dose-dependently stimulated the mRNA
expression of BDNF and NT-3 in WT, but not in Ppara null,
microglia (Figures 2E and 2F) and astrocytes (Figures 2G and
2H). Similarly, simvastatin and pravastatin stimulated the
protein expression of BDNF in WT, but not Ppara null, astro-
cytes (Figures 2I–2K) and neurons (Figures S2A and S2B).
Together, these results suggest that PPARa is involved in
the statin-mediated upregulation of neurotrophic factors in
glia and neurons.
PPARb and PPARg Are Not Involved in Statin-Induced
Expression of Neurotrophins
Simvastatin was found to stimulate the expression of PPARa,
PPARb, and PPARg in astrocytes (Figure S2C). Therefore, we
next examined the role of PPARb and PPARg in statin-induced
expression of BDNF and NT-3. Although activation of PPARg
has been shown to induce the expression of BDNF (Jin et al.,
2013; Kariharan et al., 2015), antisense knockdown of PPARg
and PPARb failed to inhibit simvastatin-stimulated expression
of BDNF and NT-3 in astrocytes (Figure S2D), suggesting that
neither PPARb nor PPARg is involved in simvastatin-mediated
upregulation of neurotrophic factors. However, it is PPARa, but
not PPARb, that is involved in statin-mediated upregulation of
neurotrophic factors, as simvastatin stimulated BDNF expres-
sion in Pparb null astrocytes (Figure S2E). The direct involvement
of PPARa in the statin-stimulated expression of neurotrophins.
Figure 1. Anti-inflammatory, but Not Neuro-
trophic, Activity of Simvastatin Depends on
Mevalonate Metabolites and Isoprenylation
of p21ras and p21rac
(A and B) Mouse astrocytes pre-treated with
different doses of farnesyl pyrophosphate (FPP)
and mevalonate for 1 hr were stimulated with
10 mM simvastatin for another 5 hr under serum-
free condition followed by mRNA analysis of neu-
rotrophins by semi-quantitative RT-PCR (A) and
real-time PCR (B). Results represent three inde-
pendent analyses. ap < 0.001 versus control-
BDNF; bp < 0.001 versus control-NT3.
(C) Astrocytes pre-treated with mevalonate, far-
nesyl pyrophosphate (FPP), and geranylgeranyl
pyrophosphate (GGPP) in the presence of 10 mM
simvastatin for 6 hr were stimulated with IL-1b
(20 ng/ml) for another 12 hr followed by analysis of
iNOS by western blot.
(D) Bands were scanned and presented as rela-
tive to control. ap < 0.001 versus control; bp <
0.001 versus IL-1b; cp < 0.001 versus IL-1b +
Simva.
(E) Astrocytes were transfected with pcDNA3
(empty vector) and dominant-negative mutants of
p21ras (DRas) and p21rac (DRac). After a 24-hr
transfection, cells were incubated with serum-free
media for 6 hr followed by analysis of mRNA
expression of BDNF and NT-3 by real-time PCR.
(F) Similarly, 24 hr after transfection, cells were
stimulated with IL-1b (20 ng/ml) for 6 hr followed
by monitoring the expression of iNOS mRNA by
real-time PCR.
(G) After transfection with control and p21ras
siRNA, cells were incubated with serum-free
media for 6 hr followed bymonitoringBdnf andNt3
mRNAs by real-time PCR.
(H) Similarly, after transfection, cells were stimu-
lated with IL-1b for 12 hr followed by analysis of
iNOS protein by western blot.
(I) Bands were scanned and presented as relative
to control. ap < 0.001 versus control; bp < 0.001
versus control-siRNA-IL-1b.
(J) Astrocytes were incubated with farnesyl
phosphotransferase inhibitor (FPTi) and ger-
anylgeranyl phosphotransferase inhibitor (GGTi)
for 6 hr followed by analysis ofBdnfmRNA by real-
time PCR.
(K) Astrocytes pretreated with FPTi and GGTi for 1 hr were stimulated with IL-1b followed by monitoring iNOS protein after a 12-hr incubation.
(L) Bands were scanned and presented as relative to control. ap < 0.001 versus control; bp < 0.001 versus IL-1b. Results represent three independent analyses.
See also Figure S1.was further confirmed when simvastatin stimulated the expres-
sion of BDNF in PPARa cDNA-, but not empty vector-transfected
Ppara null astrocytes (Figures S2F and S2G). These data suggest
that statins require only PPARa for the induction of BDNF and
NT-3 in glial cells. Consistent to the role of PPARa in the induc-
tion of neurotrophins, prototype ligands of PPARa (WY14643
and gemfibrozil) induced the expression of BDNF and NT-3 in
primary astrocytes (Figure S2H). Similar to simvastatin,
WY14643 and gemfibrozil were also unable to induce the
expression of BDNF and NT-3 in Ppara null astrocytes and
PPARa overexpression restored the ability of these ligands to
induce CREB and neurotrophins in Ppara null astrocytes
(Figure S2I).CelStatins Stimulate the Expression of BDNF and NT-3
In Vivo in Mouse Brain via PPARa
Next, we examined whether statins required PPARa (Figure S3A)
for the upregulation of neurotrophins in vivo in the brain. As
evident from RT-PCR (Figure S3B) real-time PCR (Figure S3C),
the mRNA expression of both BDNF and NT-3 was significantly
higher in WT brain than Ppara null brain. We have shown that
both simvastatin and pravastatin are able to cross the blood-
brain barrier (BBB) with variable efficiencies (Ghosh et al.,
2009). Oral administration of both pravastatin (Figures S3D and
S3E) and simvastatin (Figures S3F and S3G) significantly stimu-
lated the expression of BDNF and NT-3 in vivo in the midbrain of
WT, but not Ppara null, mice. However, in accordance with theirl Metabolism 22, 253–265, August 4, 2015 ª2015 Elsevier Inc. 255
Figure 2. PPARa Is Involved in Neurotro-
phic, but Not Anti-inflammatory, Properties
of Statins
(A–H) Astrocytes isolated from WT and Ppara null
(a KO) mice were treated with simvastatin for 6 hr
followed by stimulation with IL-1b. After 6 hr, the
mRNA expression of iNOS was monitored by RT-
PCR (A) and real-time PCR (B). Results are mean ±
SD of three independent experiments. After 24 hr,
the protein level of iNOS was monitored by west-
ern blot (C) and immunofluorescence (D). Micro-
glia (E and F) and astrocytes (G and H) isolated
from WT and a KO mice were treated with sim-
vastatin. After 6 hr, cells were analyzed for mRNA
encoding BDNF and NT-3 by RT-PCR (E and G)
and real-time PCR (F and H). ap < 0.001 versus
control-BDNF; bp < 0.001 versus control-NT-3.
(I–K) WT and a KO primary astrocytes were incu-
bated with 10 mM simvastatin (J) and pravastatin
(K) under serum-free conditions. After 24 hr, the
BDNF level was analyzed by double-label immu-
nofluorescence. Results represent three inde-
pendent experiments.
See also Figures S2 and S3.BBB permeabilities, simvastatin wasmore effective than pravas-
tatin in stimulating the expression of neurotrophins in vivo in the
brain.
Statins Interact with the Ligand-Binding Domain of
PPARa
Next, we were prompted to study how statins employ PPARa in
the expression of neurotrophic factors. It is not known whether
statins are ligands of PPARa. In order to determine whether sim-
vastatin directly interacts with the ligand-binding domain (LBD)
of PPARa, simvastatin-treated astrocytic nuclear extracts were
pulled down by the PPARa-LBD followed by electrospray ioniza-
tion tandemmass spectrometry (ESI-MS) analysis. Interestingly,
we detected the peak for simvastatin itself in the PPARa-LBD
pull-down fraction of simvastatin-treated (Figures 3B and 3D),
but not control (Figures 3A and 3C), astrocytes. Time-resolved
fluorescence resonance energy transfer (TR-FRET) is a widely
accepted technology for monitoring the physical interaction be-256 Cell Metabolism 22, 253–265, August 4, 2015 ª2015 Elsevier Inc.tween protein and ligand spaced at a
distance as low as 5 mm. We adopted
TR-FRET for analyzing the interaction be-
tween PPARa and different statins (Fig-
ure 3E). Our fluorescence dose-response
curve clearly indicated that simvastatin
(Figure 3F), mevastatin (Figure 3G), and
pravastatin (Figure 3H) dose-depen-
dently induced the TR-FRET signal from
PPARa-PGC1a complex, suggesting
that statins serve as ligand of PPARa.
For comparison, we also used atorvasta-
tin and rosuvastatin and found that
the signal strength of emitted fluores-
cence was the highest for simvastatin
among simvastatin, mevastatin, pravas-
tatin, atorvastatin, and rosuvastatin (Fig-ure 3I), suggesting that simvastatin is the strongest ligand of
PPARa among different statins. Our observation was further
corroborated once we compared EC50 value of different statins
after 30 min of interaction with PPARa. The EC50 value of simva-
statin (4.26) was lower than pravastatin, mevastatin, atorvasta-
tin, and rosuvastatin further suggesting that simvastatin is the
strongest ligand of PPARa among different statins. GW7642, a
well-known PPARa agonist, displayed similar dose-response
curve (Figure 3F) under similar condition with much lower EC50
value (1.11), indicating that the binding affinity of statins to
PPARa is still lower than its prototypic ligands.
To characterize the interaction between simvastatin and
PPARa in a molecular level, we carried out in silico docking
studies of simvastatin with PPARa-LBD. These studies gener-
ated a reasonable docked pose of the simvastatin molecule in
the ligand-binding pocket (Figure 4A). The docked pose of sim-
vastatin showed two potential hydrogen bonds between the
statin ligand and two active-site residues, Tyr334 (Y334) and
Figure 3. A High-Throughput Analysis to
Study the Interaction between PPARa and
Statin
(A–D) PPARa-LBD affinity-purified nuclear fraction
extracted from control (A) and simvastatin-treated
(B) primary astrocytes was analyzed by electro-
spray ionization tandem mass spectrometry.
Counts versus retention time shows the peak of
simvastatin at 4.56 min in simvastatin-treated, but
not control, sample. The magnified view of counts
versus mass-to-charge ratio clearly shows the
peak of simvastatin in the simvastatin-treated (D),
but not control (C), sample.
(E) To identify stain group of drugs as ligand
of PPARa, time-resolved fluorescence energy
transfer (TR-FRET) technology was adopted.
Successful binding of statin with PPARa
would transfer fluorescence energy from Terbium
(Tb)-tagged anti-GST antibody to Fluorescein
(FL)-tagged PGC-1a co-activator. The optimum
level of emitted fluorescence was measured at
400 m-second integration time and 40 m-second
delay time set in Molecular Device Analyst
instrument.
(F–H) Fluorescein emission was recorded with
increasing doses of (F) simvastatin, (G) pravasta-
tin, and (H) mevastatin.
(I) TR-FRET was also performed for atorvastatin
and rosuvastatin and maximum emitted fluores-
cence was compared among different statins.
Results represent three independent analysis.Leu331 (L331) (Figure 4B), of the PPARa-LBD. After obtaining a
suitable docked pose of the simvastatin, we attempted to
compute the apparent binding energy of the ligand along with
the strain energy. Using the MM-GBSA approach, we found
the binding energy of simvastatin to be –36.0 Kcal/mol with
minimal strain energy of 0.71 Kcal/mol, suggesting a strong
interaction between simvastatin and PPARa. Imposing the
most stringent docking protocols, a reasonable docked pose
of simvastatin was obtained for PPARa, with a total score of
8.27, a polar score of 1.54, and a crash score of –0.71. Interest-
ingly, by applying similar docking protocols, we failed to obtain
any dock pose of simvastatin for both PPARb and PPARg, sug-
gesting that the interaction of simvastatin with PPARa-LBD is
specific and not possible with other PPAR isoforms. However,
in silico modeling of protein-ligand interaction is hypothetical
and requires rigorous experimental analysis for further validation.
Therefore, we performed lentivirus-mediated de novo ex-
pression studies, where we overexpressed wild-type (GFP-
FLPpara) and statin-binding domain (SBD) mutated PPARa
(GFP-DsbdPpara) gene in Ppara null astrocytes followed by the
binding analyses with simvastatin. Briefly, we performed site-Cell Metabolism 22, 253–26directed mutagenesis in mouse PPARa
gene where we replaced Leu331 residue
with methionine (L331M) and Tyr334 res-
idue with aspartate (Y334D). After that,
we cloned the entire mouse GFP-Ppara
gene and L331M/Y334D Ppara (GFP-
DsbdPpara) gene in the pLenti6∕V5-
TOPO lentiviral expression vector, pack-aged in lentivirus particle with the help of HEK293FT cells,
transduced mouse astrocytes with lentiviral particles for 48 hr,
purified full-length (GFP-FLPPARa) and mutated PPARa (GFP-
DsbdPPARa) proteins in a GFP-affinity column, and finally
performed thermal shift assay in order to analyze their conforma-
tional stability. Both full-length (Figure 4C) and mutated (Fig-
ure 4D) proteins displayed similar pattern of thermal shift with
equivalent melting temperature (Tm), suggesting that mutations
in L331 and Y334 residues did not alter the conformational sta-
bility of PPARa. In another experiment, Ppara null astrocytes
transduced with different lentiviral PPARa constructs were incu-
bated with simvastatin for 2 hr and then performed ESI-MS ana-
lyses in the GFP-affinity purified nuclear fraction of astrocytes.
Interestingly, we observed a very specific peak of simvastatin
in the nuclear extract of GFP-PPARa (Figures 4Ei and 4Eii), but
neither in empty GFP vector-transduced (Figures 4Eiii and
4Eiv) nor GFP-DsbdPpara-transduced (Figures 4Ev and 4Evi) nu-
clear extracts of astrocytes, suggesting that Leu331 and Tyr334
residues are indeed essential for binding with statin. Next, we
examined if these two amino acidswere required for statin-medi-
ated activation of PPARa. We measured PPRE-driven luciferase5, August 4, 2015 ª2015 Elsevier Inc. 257
Figure 4. Proteomic Analysis of Interaction
between PPARa and Simvastatin
(A) Ribbon representations of the docked complex
of PPARa (3VI8.pdb, X-ray, green) and simvastatin
show the distribution of amino acids within a
5.00-A˚ distance of simvastatin.
(B) Magnified view of the docking site shows the
interaction between simvastatin and Leu331 and
Tyr334.
(C and D) Thermal shift assay of (C) full-length
(GFP-FLPpara) and (D) statin-binding domain
mutated (GFP-DsbdPpara) PPARa was per-
formed.
(E) De novo binding assay of simvastatin where
mouse astrocytes transduced with FLPpara and
DsbdPpara constructs were treated with simva-
statin for 2 hr, nuclear extracts were isolated,
passed through GFP column for affinity-purifica-
tion, and then analyzed by ESI-MS. Representative
counts versus acquisition time ratio of simvastatin
analyzed in the nuclear extracts of GFP-trans-
duced (i and ii), GFP-FLPpara-transduced (iii and
iv), and GFP-DsbdPpara-transduced (v and vi)
astroglial cells.
(F) PPRE-driven luciferase activity in FLPpara and
DsbdPpara-transduced Ppara null astrocytes after
treatment with simvastatin (top), pravastatin (mid-
dle), and mevastatin (bottom). Results are mean ±
SD of three independent experiments. ap < 0.001
versus control; bp < 0.001 versus FLPpara.
(G and H) Docked poses of gemfibrozil (G) and
WY14673 (H) in PPARa ligand binding core.
(I and J) PPRE-driven luciferase activity in FLPpara
and DsbdPpara-transduced Ppara null astrocytes
after treatment with WY14643 (I) and gemfibrozil
(J). Results are mean ± SD of three independent
experiments.activity in both FLPpara and Dsbd Ppara-transduced Ppara null
astrocytes after treatment of simvastatin, mevastatin, and pra-
vastatin. Interestingly, we observed that different statins stimu-
lated PPRE-luciferase activity in FLPpara-transduced, but not
in DsbdPpara-transduced, astrocytes (Figure 4F), suggesting
that statins require these two amino acids for the activation of
PPARa.
Next, we investigated if WY14643 and gemfibrozil, classical li-
gands of PPARa, also required Leu331 and Tyr334 residues for
the activation PPARa. Gemfibrozil (Figure 4G) and WY14643
(Figure 4H) were allowed to dock in the LBD of PPARa using
the similar docking protocols used to dock simvastatin. We
found that both the compounds docked very nicely with a
good docked scores and with very little penalty scores. How-
ever, the binding poses of gemfibrozil (Figure 4G) and
WY14673 (Figure 4H) were very different from that of simva-
statin. Simvastatin showed potential hydrogen bonds with
L331 and Y334 but gemfibrozil and WY14673 were 6 A˚ and258 Cell Metabolism 22, 253–265, August 4, 2015 ª2015 Elsevier Inc.5 A˚ away from these residues, suggest-
ing that these two known ligands of
PPARa do not interact with L331 and
Y334 residues. Consistently, gemfibrozil
(Figure 4I) and WY14643 (Figure 4J)
stimulated PPRE-luciferase activity inDsbdPpara-transduced Ppara null astrocytes almost similar to
that found FLPpara-transduced cells, confirming that these
two ligands do not require L331 and Y334 residues for the acti-
vation of PPARa.
Statins Increase CREB via PPARa-Mediated
Transcriptional Regulation
Different statins (Figure 5A for mevastatin, pravastatin, and sim-
vastatin; Figure 5B for atorvastatin and rosuvastatin) induced
PPARa response element (PPRE)-driven reporter activity,
revealing that different statins are capable of activating PPARa
in astrocytes. However, detailed analysis of BDNF and NT-3 pro-
moters showed no PPRE, ruling out the direct involvement
of PPARa in the upregulation of neurotrophic factors. On the
other hand, a number of CRE sequences were found in BDNF
and NT-3 promoters. Accordingly, antisense knockdown of
CREB suppressed the expression of CREB and inhibited the
simvastatin-induced expression of BDNF and NT-3 in mouse
Figure 5. The Role of PPARa, PPARb,
and PPARg in Transcriptional Regulation
of CREB
(A–E) Mouse astrocytes were transfected with
PPRE luciferase and after a 24-hr transfection,
cells were treated with mevastatin, pravastatin,
simvastatin (A), atorvastatin, and rosuvastatin (B)
for 4 hr, followed by the luciferase assay. Activa-
tion of WT CREB promoter by pravastatin, sim-
vastatin (C), atorvastatin, and rosuvastatin (D) in
astrocytes isolated from WT and Ppara null (aKO)
mice. Activation of WT and mutated CREB pro-
moter by mevastatin, pravastatin, and simvastatin
inmouse astrocytes (E). Results aremeans ± SDof
three independent experiments. ap < 0.001 versus
control.
(F–H) The ChIP assay for PPARa (F), PPARb (G)
and PPARg (H) in pravastatin-treatedWT and aKO
astrocytes.
(I–K) The ChIP assay for PPARa (I), PPARb (J), and
PPARg (K) in simvastatin-treated WT and aKO
astrocytes. Results represent three separate
analyses.
See also Figures S3 and S5.astrocytes (Figure S4A). Similarly, we observed that CREB
siRNA, but not control siRNA, inhibited simvastatin-induced
expression of BDNF in astrocytes (Figure S4B). These results
indicate the involvement of CREB in simvastatin-mediated upre-
gulation of neurotrophic factors.
Although we did not find any PPRE in BDNF and NT-3 pro-
moters, analysis of the CREB promoter revealed the presence
of a conserved PPRE (–1,152 to –1,164 bp upstream of the start
sequence) prompting us to study the involvement of PPARa in
the transcriptional regulation of CREB. Different statins stimu-
lated the expression of CREB mRNA in mouse astrocytes and
microglia (Figure S4C). However, statins upregulated the expres-
sion of CREB mRNA in astrocytes and microglia isolated from
WT, but not Ppara null, mice (Figure S4D). Immunofluorescence
analysis also showed that simvastatin upregulated CREB protein
in astrocytes isolated from WT, but not Ppara null, mice (Fig-
ure S4E). Similarly, simvastatin also upregulated the expression
of CREBmRNA (Figure S4F) and protein (Figure S4G) in neuronsCell Metabolism 22, 253–26isolated from WT, but not Ppara null,
mice. A lower abundance of CREB in
different parts of the brain of Ppara null
animals than of WT and Pparb null
animals further shows that PPARa, but
not PPARb, controls the expression of
CREB in vivo in the brain (Figures S3H
and S3I). Oral administration of simva-
statin was also observed to stimulate
the expression of CREB in vivo in the cor-
tex of WT, but not Ppara null, mice (Fig-
ure S3J), indicating the role of PPARa
in the statin-stimulated expression of
CREB in the brain.
Next, we investigated whether rein-
statement of PPARa helps statins to
induce the expression of CREB in Pparanull cells. PPARa overexpression increased the basal level of
CREB in Ppara null astrocytes (Figure S4H). Although simva-
statin was unable to increase the mRNA expression of CREB in
Ppara null neurons, we observed stimulation of CREB mRNA
expression by simvastatin in Ppara null neurons after PPARa
overexpression (Figure S4H). Immunocytochemical analyses
also revealed that ectopic overexpression of PPARa in primary
human neurons stimulated basal expression of CREB (Fig-
ure S4K) compared with untransfected (Figure S4I) or pcDNA-
transfected (Figure S4J) cells and that simvastatin stimulation
further increased the level of CREB in PPARa-overexpressed
cells (Figure S4K). On the other hand, a dominant-negative
mutant of human PPARa (DPPARa) abrogated the expression
of CREB, and simvastatin also failed to stimulate the expression
of CREB in DPPARa-expressed human neurons (Figure S4L).
To further analyze the role of PPARa in the transcription of
Creb, we cloned the mouse Creb promoter and then performed
site-directed mutagenesis to mutate the PPRE as described5, August 4, 2015 ª2015 Elsevier Inc. 259
(Roy et al., 2013). Different statins markedly induced Creb pro-
moter-driven luciferase activity in astrocytes isolated from WT,
but not Ppara null, mice (Figure 5C for pravastatin and simva-
statin; Figure 5D for atorvastatin and rosuvastatin). However, in
WT astrocytes, statins remained unable to induce luciferase ac-
tivity driven by a Creb promoter in which PPRE was mutated
(Figure 5E). Next, we performed chromatin immunoprecipitation
(ChIP) analysis in which the recruitment of PPARa to the Creb
promoter was monitored in untreated and statin-treated astro-
cytes. After immunoprecipitation of chromatin fragments by
antibodies against PPARa, we were able to amplify a 144-bp
fragment encompassing the PPRE of theCreb promoter in astro-
cytes isolated from wild-type, but not Ppara null, mice (Figures
5F and 5I). On the other hand, no amplification product of the
Creb promoter was observed in any of the immunoprecipitates
obtained with PPARb, PPARg, or control IgG (Figures 5G, 5H,
5J, and 5K), suggesting that PPARa, but neither PPARb nor
PPARg, is recruited to the PPRE of the Creb promoter in astro-
cytes. Both pravastatin (Figure 5F) and simvastatin (Figure 5I)
increased the recruitment of PPARa, but neither PPARb nor
PPARg (Figures 5G, 5H, 5J, and 5K), to the Creb promoter in
astrocytes.
Evaluating the Role of Leu331 and Tyr334 of PPARa in
the Statin-Induced Expression of BDNF in Cultured
Astrocytes and In Vivo in Mouse Brain
Next, we examined if Leu331 and Tyr 334 residues of PPARa
were required for statin-mediated upregulation of CREB and
BDNF in the cultured astrocytes as well as in vivo in the brain.
Mouse primary astrocytes isolated from Ppara null mice were
transduced with EGFP-constructed lentiviral particles contain-
ing either FLPpara or DsbdPpara. Transduction efficiency was
more than 90% for both the constructs (Figure 6A). Interestingly,
simvastatin significantly upregulated the expression of CREB
and BDNF (Figures 6B and 6C) in FLPpara-transduced astro-
cytes, but neither in DsbdPpara- nor empty vector-transduced
astrocytes, which we further confirmed by BDNF ELISA from
the astroglial supernatants (Figure 6D). Since BDNF is the major
neurotrophic factor that controls the function of hippocampus,
we targeted the hippocampus for lentiviral manipulation of the
Ppara gene. GFP-FLPpara and GFP-DsbdPpara lentiviral parti-
cles were infused bilaterally in the pyramidal layer of the CA2
region and in the subgranular layer of the dentate gyrus (DG) of
6- to 8-week-old Ppara null mice as described earlier (Roy
et al., 2013). Three weeks after the infusion, we observed a
marked distribution of EGFP constructed PPARa in the entire py-
ramidal (CA1, CA2, and CA3) and DG region (Figure 6E), indi-
cating the distribution efficiency of FLPpara and DsbdPpara in
our proposed injection coordinates. Simvastatin feeding was
started after 6 weeks of lentiviral injection and continued for
2 weeks. Consistent with cell culture results, our immunofluores-
cence and immunoblot analyses revealed that the bilateral infu-
sion of lentiviral GFP-FLPpara, but neither empty vector nor
GFP-DsbdPpara, strongly upregulated the expression of CREB
(Figures 6G and 6H) and BDNF (Figures 6F–6I) in the hippocam-
pus of simvastatin-fed mice, suggesting that both L331 and
Y334 residues of PPARa are critical for the statin-mediated up-
regulation of CREB and BDNF.
Next, we wanted to determine whether the simvastatin-
mediated upregulation of BDNF production could improve hip-260 Cell Metabolism 22, 253–265, August 4, 2015 ª2015 Elsevier Incpocampus-dependent spatial learning and memory in these
animals. Therefore, we performed Barnes maze analyses after
oral administration of simvastatin (1 mg/kg body weight/day) to
FLPpara and DsbdPpara animals for 2 weeks. Since these ani-
mals were all on the Ppara null background, they spent similar
time before entering into the hole (Figure 6L). However, FLPpara
mice spent more time in the target quadrant (Q1) after statin
feeding when compared to statin-fed Ppara null mice (F3,28 =
2.87; p % 0.05) or statin-fed DsbdPpara mice (F3,28 = 3.57;
p % 0.05) (Figures 6J and 6K). Moreover, the number of errors
is significantly less in statin-fed FLPpara mice (Figure 6M) as
compared to statin-fed DsbdPpara (F3,28 = 3.14; p% 0.05) and
statin-fed Ppara null mice (F3,28 = 13.07; p % 0.01), suggesting
that both L331 and Y334 residues of PPARa are crucial for the
statin-induced hippocampus-dependent learning and memory.
Validating the PPARa-Mediated Neurotrophic Effect of
Statin in FAD5X Mouse Model of AD
In order to analyze the therapeutic importance of PPARa
in statin-mediated upregulation of BDNF, we used FAD5X
(B6SJL-Tg(APPSwFlLon,PSEN1*M146L*L286V)6799Vas/J)
transgenicmousemodel of AD.We generated FAD5Xmice in the
homozygous Ppara null background (Figure 7A). Five-month-old
non-Tg, FAD5X, Ppara null, and FAD5X/Ppara null mice were fed
simvastatin (1mg/kg bodyweight/day) for 2weeks. Interestingly,
we observed that simvastatin increased the astroglial expression
of BDNF in cortex (Figures 7B–7E) of WT (Figure 7B) and FAD5X
animals (Figure 7D), but not in Ppara null (Figure 7C) and FAD5X/
Ppara null mice (Figure 7E), suggesting that PPARa regulates the
expression of BDNF during AD-like pathology. Similarly, our
immunoblot (Figures 7F and 7G) and ELISA (Figure 7H) analyses
revealed that both WT and FAD5X, but neither Ppara null nor
FAD5X/Ppara null, mice showed upregulated expression of
BDNF after simvastatin treatment, suggesting the therapeutic
prospect of PPARa in AD. Next, we validated the effect of statin
in the process of learning and memory in these animals by
analyzing their performance in Barnes maze. Upon simvastatin
treatment, both wild-type and FAD5X mice exhibited significant
improvement in memory performance on Barnes maze test as
shown by errors (Figure 7I) (F1,14 = 1.4 [>Fc = 0.34] between unfed
and simvastatin-fedWT; F1,14 = 1 [>Fc = 0.26] between unfed and
simvastatin-fed FAD5X) and latency (Figure 7J) (F1,14 = 3.59
[>Fc = 1.72] between unfed and simvastatin-fed WT; F1,14 =
3.78 [>Fc = 2.87] between unfed and simvastatin-fed FAD5X).
However, Ppara null and FAD5X/Ppara null mice showed no
improvement after simvastatin feeding (Figures 7I and 7J). Sim-
vastatin treatment did not significantly alter body weight (Fig-
ure 7K), stereotypy (Figure 7L), total distance (Figure 7M), and
horizontal activity (Figure 7N) in all groups of mice, suggesting
that either simvastatin treatment or genetic alteration do not
modulate gross metabolic and motor activities.
DISCUSSION
Statins Induce Neurotrophins in Brain Cells
Both BDNF and NT-3 are important for preserving the complex
neuronal architecture of hippocampal and cortical circuits.
Therefore, increasing the levels of neurotrophins in the CNS is
considered to be an important step in halting the progression
of several neurodegenerative and neurocognitive diseases..
Figure 6. Lentiviral Manipulation of
FLPpara and DsbdPpara in the Adult Brain
Hippocampus and Its Role in Statin-Stimu-
lated Expression of BDNF
(A) Astrocytes isolated from Ppara null (aKO) mice
were transduced with GFP-FLPpara and GFP-
DsbdPpara to analyze the transduction efficiency
of our plasmids.
(B) Expression of CREB and BDNF were checked
by immunoblot analysis.
(C) Bands were scanned and presented as relative
to control. Results are mean ± SD of three inde-
pendent experiments. ap < 0.001 versus lenti-
FLPpara control-CREB; bp < 0.001 versus lenti-
FLPpara control-BDNF.
(D) BDNF expression was confirmed by ELISA
from the respective supernatants. ap < 0.001
versus lenti-vector control; bp < 0.05 versus lenti-
FLPpara control.
(E) Both of these constructs were injected bilat-
erally in the hippocampus of 6- to 8-week-oldmale
C57BL/6 mice with coordinates of 2.54 mm AP
axis, 1.30mmML (CA2 layer) and 1.80mmML (SG
layer of DG) axis, and 2.4mmDV axis. Each animal
received four injections with two injections per
hemisphere. After 3 weeks, the distribution of
lentivirus was detected by microscopic analysis of
GFP. Injection sites were magnified and shown in
side panels.
(F) After 2 weeks of simvastatin feeding, the
expression of BDNF in GFAP-immunoreactive
astrocytes were analyzed (green, GFP-PPARa;
red, GFAP; blue, BDNF).
(G) CREB and BDNF expression were analyzed
by immunoblot in the hippocampal extracts
of GFP, GFP-FLPpara, and GFP-DsbdPpara
animals.
(H) Bands were scanned and presented as relative
to control. ap < 0.05 versus simvastatin; bp < 0.01
versus lenti-FLPpara-simvastatin.
(I) Expression of BDNF was confirmed by ELISA.
ap < 0.01 versus simvastatin; bp < 0.01 versus
lenti-FLPpara-simvastatin.
(J) Performances of statin-fed FLPpara and
DsbdPpara animals (n = 5 per group) in Barnes
maze were compared with statin-fed aKO mice.
Target hole placed in first quadrant (Q1) is shown
as red.
(K–M) Total time spent in all four quadrants (Q1–Q4), (L) latency and (M) errors were calculated. ap < 0.05 (= 0.041) versus statin-fed Ppara null and bp < 0.05
(= 0.037) versus statin-fed FLPpara. *p < 0.01 versus statin-fed aKO and **p < 0.05 (= 0.045) versus statin-fed DsbdPpara (0.0015) animals.Because these neurotrophic molecules do not cross the BBB,
gene therapy and stereotaxic injection directly into the brain
are now the only available options. However, from the therapeu-
tic perspective, it seems that the best option would be to
stimulate/induce the production of BDNF and NT-3 in vivo in
the CNS of patients with neurodegenerative disorders. Here,
we describe the finding that statins are capable of upregulating
neurotrophic factors in brain cells and in vivo in the brain.
Although previous studies have reported the neurotrophic role
of statins in stroke (Chen et al., 2005) and depression (Tsai,
2007), nothing is known about the role of statins in controlling
the expression of neurotrophic factors. According to Tsai
(2007), statins may be involved in the upregulation of plasmin
(t-PA) and cleavage of pro-BDNF to mature BDNF. However,Celthis study does not provide any data on the transcriptional upre-
gulation of BDNF by statins.
A Tale of Two Independent Pathways Regulated by
Statins
Statins inhibit HMG-CoA reductase, the regulatory enzyme in the
cholesterol biosynthesis pathway and thereby lower the level of
cholesterol in patients with hypercholesterolemia. However, sta-
tins are also anti-inflammatory (Cordle and Landreth, 2005;
Pahan et al., 1997). Although this anti-inflammatory activity
of statins is independent of cholesterol, intermediates of the
mevalonate pathway abrogate this anti-inflammatory effect (Pa-
han, 2006; Roy and Pahan, 2011), and statins employ the isopre-
nylation-p21ras/p21rac pathway to upregulate proinflammatoryl Metabolism 22, 253–265, August 4, 2015 ª2015 Elsevier Inc. 261
Figure 7. Simvastatin Increases BDNF in the Brain of FAD5X Mice via PPARa
(A–E) Genotyping of FAD5X/Ppara null (5X/aKO) mice. Five-month-old mice were fed simvastatin for 2 weeks followed by immunofluorescence analysis of
astroglial BDNF (GFAP, red; BDNF, green) in the cortices of (B) wild-type (WT), (C) aKO, (D) FAD5X, and (E) FAD5X/aKO animals.
(F and G) Immunoblot (F) and densitometric (G) analyses of CREB and BDNF were performed in the hippocampal extracts.
(H) ELISA of BDNF in the hippocampal extracts.
(I and J) Number of errors (I) and latency (J) in Barnes maze for statin unfed and fed WT, aKO, FAD5X, and FAD5X/aKO.
(K–N) All groups of mice were also monitored for body weight (K), stereotypy (L), total distance (M), and horizontal activity (N). Eight mice (n = 8) were used in each
group. *p < 0.05 versus statin-unfed wild-type control and **p < 0.05 versus statin-unfed FAD5X mice.
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molecules (Cordle et al., 2005; Roy and Pahan, 2011). Currently,
in addition to cholesterol-lowering, statins are known to inhibit
small G protein activation, suppress proinflammatorymolecules,
modulate the adaptive immune response, stimulate endothelial
NOS, attenuate migration and proliferation of smooth muscle
cells, lower the production of reactive oxygen species, destabi-
lize amyloid-b fibrils, attenuate a-syn aggregation, and mitigate
dyskinesia (Pahan, 2006; Roy and Pahan, 2011; Weber et al.,
2005). In fact, all these functions are dependent on their ability
to suppress either intermediates or the end product of themeval-
onate pathway. By contrast, here, we have found that metabo-
lites of the cholesterol biosynthetic pathway, including FPP
and mevalonate, inhibitors of isoprenoid transferring enzymes
(FPTi and GGTi), and dominant-negative mutants of p21ras and
p21rac, are unable to modulate statin-mediated upregulation of
neurotrophic factors, suggesting that statin-mediated inhibition
of the cholesterol biosynthetic pathway and/or the isoprenoid-
p21ras/p21rac pathway is/are not involved in the upregulation of
neurotrophic factors.
On the other hand, as expected, CREB, a classical transcrip-
tion factor regulating the synthesis of many neurotrophic factors,
was found to be involved in statin-mediated upregulation of neu-
rotrophic factors. Next, we explored the effect of statins on the
transcriptional regulation of CREB. Interestingly, promoter anal-
ysis of CREB, but not BDNF or NT-3, revealed the presence of a
conserved PPRE sequence in its promoter, and we found the
involvement of PPARa, but not PPARb or PPARg, in statin-medi-
ated upregulation of CREB and neurotrophic factors. ChIP anal-
ysis also showed that simvastatin induced the recruitment of
PPARa, but not PPARb or PPARg, to the CREB promoter.
Together, our results suggest that statins upregulate neurotro-
phic factors via a novel PPARa-CREB pathway that is indepen-
dent of their inhibition of the mevalonate pathway. Therefore,
statins employ two distinct pathways to execute their biolog-
ical functions: suppressing the mevalonate pathway for their
previously known biological functions and stimulating the
PPARa-CREB pathway for their neurotrophic function (Graphical
Abstract).
Apart from neurotrophins, CREB-regulated genes are also
involved in the modulation of our basic metabolic processes,
including glucose metabolism, fatty acid oxidation, and hepatic
lipid mobilization. CREB activates hepatic gluconeogenesis
and fatty acid b-oxidation by inducing the expression of PGC-1
and Hes-1 (Herzig et al., 2003) genes. CREB-mediated upregu-
lation of the hepatocyte nuclear factor-4 (HNF-4) gene stimu-
lates the lipid mobilization process in liver (Dell and Hadzopou-
lou-Cladaras, 1999). Therefore, downregulation of CREB and
many other CREB-regulated genes may contribute to different
metabolic disorders, including diabetes, arthritis, and obesity.
Thus, the importance of our finding is that statins, one of the
most commonly used groups of drugs, may be used to modulate
multiple metabolic states via PPARa-mediated upregulation
of CREB.
Statins Serve as Ligands of PPARa
For the last 30 years, statins have been widely considered to be
competitive inhibitors of HMG-CoA reductase. However, until
now there has been no receptor protein identified for statins.
Here, we report that PPARa, but not PPARb or PPARg, servesCelas a receptor for statins. Detailed energy calculations for
simvastatin:PPAR complexes shows greater thermodynamic
stability of simvastatin:PPARa than either simvastatin:PPARb
or simvastatin:PPARg. Our TR-FRET analysis with increasing
doses of different statins in PPARa-PGC-1a complex, in silico
interaction studies, de novo expression studies of full-length
and mutated constructs PPARa followed by ESI-MS analyses,
and ESI-MS analysis of PPARa-LBD pull-down from the nuclear
fraction confirm the feasibility and stability of the simvastatin:
PPARa complex. Among simvastatin, mevastatin, pravastatin,
atorvastatin, and rosuvastatin, simvastatin was found to be the
strongest ligand of PPARa followed by mevastatin. On the other
hand, ligand-binding efficacies of pravastatin, atorvastatin, and
rosuvastatin were almost same. According to our detailed struc-
tural and molecular techniques, we confirmed that Leu331 and
Tyr334 residues of PPARa LBD are important for statin-binding
as L331M/Y334D PPARa did not show any interaction with sta-
tins. Interestingly, known ligands of PPARa such as WY-14643
and gemfibrozil did not show interaction with Leu331 and
Tyr334 residues. WhileWY-14643 and gemfibrozil docked nicely
at the ligand-binding pocket, these ligands were 6 A˚ and 5 A˚
away from Leu331 and Tyr334 residues and mutation of these
residues also did not abrogate the ability of these ligands to acti-
vate PPARa. These results identify statins as a different group of
PPARa ligands that differ from classical ligands in terms of bind-
ing to the PPARa LBD. Since PPARa plays an important role in
fatty acid oxidation, lipoprotein metabolism, and peroxisome
proliferation (Pahan, 2006), our present finding suggests that sta-
tins may also regulate these biological processes via PPARa.
Simvastatin IncreasesBDNFand ImprovesMemory in an
Animal Model of AD via PPARa
Simvastatin treatment increasedBDNF in hippocampus and cor-
tex and improved memory and learning in the FAD5X mouse
model of AD. In contrast, simvastatin remained unable to stimu-
late BDNF in CNS tissues and increase memory and learning in
FAD5X/Ppara null mice, suggesting a critical role of PPARa in
the upregulation of neurotrophins in the CNS and protection of
memory during AD pathology. Since upregulation of BDNF in
the hippocampus and the cortex has therapeutic potential for
AD, simvastatin may be beneficial for AD. However, a number
of evidences from randomized clinical trials using simvastatin
consistently report no benefit in cognition or dementia preven-
tion (Sano et al., 2011; Stadelmann et al., 2002). In some cases,
studies failed to provide clear evidence for its therapeutic effi-
cacy in AD (Burgos et al., 2012), calling into question the
relevance of preclinical and epidemiologic findings. Again,
decreased neuronal cholesterol synthesis has been implicated
as a contributor to neurodegeneration (Karasinska and Hayden,
2011; Liu et al., 2010; Valenza et al., 2010) and impaired CNS
function in the context of diabetes/insulin resistance (Suzuki
et al., 2010). Here, our findings disclose a new site of action
(PPARa) for statin that could be predictive of therapeutic benefit
in AD patients. However, a recent study indicates that women
with high level of LDL cholesterol show increased loss of visual
memory when prescribed with fenofibrate, a known ligand of
PPARa, over 7 years (Ancelin et al., 2012). This may be due to
the facts that higher LDL cholesterol is associated with better
memory functioning among the elderly without ApoE4 allelel Metabolism 22, 253–265, August 4, 2015 ª2015 Elsevier Inc. 263
(West et al., 2008) and that long-term use of fenofibrate affects
visual memory via reducing LDL cholesterol. Therefore, the rele-
vance of the statin-PPARa-CREB connection in humans remains
to be established.
EXPERIMENTAL PROCEDURES
Isolation of Mouse Primary Astroglia and Microglia
Microglia and astroglia were isolated from mixed glial cultures of 7-day-old
mouse pups according to the procedure of Giulian and Baker (1986) as
described earlier (Dasgupta et al., 2003; Roy et al., 2006).
Isolation of Human Fetal Neurons
Primary human neurons were isolated from human fetal brain tissues as
described by us earlier (Jana and Pahan, 2004a, 2004b). All of the experimental
protocols were reviewed and approved by the Institutional Review Board of
the Rush University Medical Center.
Transfection of Neurons
Primary neurons were transfected with Lipofectamine PLUS (Invitrogen) and
Nupherin-neuron (Biomol) as described by us earlier (Saha and Pahan,
2007). Briefly, each well of 6-well plate was transfected with 0.25 mg of DNA
complexed with Neupherin peptide and Lipofectamine PLUS.
ChIP
ChIP was performed as described earlier (Roy et al., 2013).
RT-PCR Analysis
Total RNAwas digestedwith DNase andRT-PCRwas carried out as described
earlier (Ghosh et al., 2009; Roy et al., 2013).
Real-Time PCR Analysis
Quantitative real-time PCR was performed in the ABI-7500 standard PCRs
(Applied Biosystems) as described earlier (Ghosh et al., 2009; Roy et al.,
2013) using TaqMan Universal Master mix and FAM-labeled probes and
primers (Applied Biosystems).
Cloning of the Creb Promoter and Site-Directed Mutagenesis
CREB promoter was cloned and subjected to site-directed mutagenesis as
described earlier (Roy et al., 2013).
Lentiviral Cloning of FL PPARa and L331M/Y334D PPARa
Please see the Supplemental Experimental Procedures.
Lentiviral Administration of FLPPARa and DPPARa in the Adult
Mouse Hippocampus
Lentiviral administration was performed as described earlier (Roy et al., 2013).
Breeding and Development of FAD5X/Ppara Null Animals
Please see the Supplemental Experimental Procedures.
ESI-MS Analysis of PPARa-Simvastatin Interaction
Please see the Supplemental Experimental Procedures.
In Silico Structural Analyses of PPARa, PPARb, and PPARg
Complexed with Simvastatin
Please see the Supplemental Experimental Procedures.
TR-FRET Analysis
TR-FRET was performed using Lanthascreen TR-FRET PPAR-alpha coactiva-
tor assay kit. In this assay, statins were incubated with GST-tagged recombi-
nant PPARa LBD, Terbium (Tb)-tagged anti GST antibody, and fluorescein
(FL)-tagged PGC-1a as directed in the manufacturer’s protocol. The entire re-
action was set up in corning 384-well plate by an automated robotic injector.
Plate was centrifuged, incubated in dark for 30 min, and then analyzed in
molecular devices analyst equipped with dichroic mirror. The excitation and
emission were set at 340 nm and 540 nm, respectively.264 Cell Metabolism 22, 253–265, August 4, 2015 ª2015 Elsevier IncThermal Shift Assay
Thermal shift assay was performed in Applied Biosystems 7500 standard real-
time thermal cycler with thermal shift dye kit (Life Technologies). For each
reaction, purified protein (0.5 mg to 1 mg) was added to 18 ml of thermal shift
buffer and 1–2 ml of dye. Reaction was set 96-well PCR plate in dark and
then placed in the thermal cycler using the following two-stage program
([25C for 2 min] 1 cycle; [27C for 15 s, 26C for 1 min] 70 cycles; auto incre-
ment 1C for both stages). The filter was set at ROX with no quencher filter and
no passive filter.
Statistical Analyses
All values are expressed as the mean ± SD. Differences among means were
analyzed using one- or two-way ANOVAwith time or genotype as the indepen-
dent factors. Differences in behavioral measures were examined by indepen-
dent one-way or repeated-measures ANOVAs using SPSS. Homogeneity of
variance between test groups was examined using Levene’s test. Post hoc
analyses of between-subjects effects were conducted using Scheffe’s,
Tukey’s or Games-Howell tests, where appropriate. p < 0.05 was considered
statistically significant.
SUPPLEMENTAL INFORMATION
Supplemental Information includes Supplemental Experimental Procedures
and four figures and can be found with this article online at http://dx.doi.org/
10.1016/j.cmet.2015.05.022.
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